Raloxifene 60 mg

Raloxifene 60 mg contains raloxifene hydrochloride, a SERM. In medical practice it is used for osteoporosis treatment and prevention in postmenopausal women, and for reducing the risk of invasive breast cancer in high-risk women. In non-medical bodybuilding contexts, it is commonly referenced for gynecomastia management during aromatizing cycles. Such use falls outside approved medical indications.

In medical practice, the recommended dose is one 60 mg tablet daily, which may be taken any time of day without regard to meals. In non-medical bodybuilding contexts, 60 mg daily is the most commonly referenced dose for gynecomastia management, with some protocols using a 120 mg loading dose for the first two weeks. Dosing should be individualized.

Raloxifene is not part of standard post-cycle therapy, which focuses on restoring endogenous testosterone production. PCT compounds like Nolvadex and Clomid are more commonly referenced for this purpose. Raloxifene's role is generally limited to on-cycle gynecomastia management.

Raloxifene hydrochloride is a SERM that binds to estrogen receptors and acts as an estrogen agonist in bone and an antagonist in breast tissue. This tissue selectivity means it can block estrogen's effects in breast tissue while maintaining estrogen's beneficial effects on bone. In bodybuilding contexts, this mechanism is used to manage gynecomastia without systemic estrogenic side effects.

Following oral administration, raloxifene reaches maximum plasma concentration at approximately 27.7 hours, with a terminal elimination half-life of about 27.7 hours. For gynecomastia management, forum discussions emphasize that results require months of consistent use, as the effect is about duration and total exposure rather than a short-term intervention.

There is no single SERM that is universally best for gynecomastia. Raloxifene is noted for its tissue selectivity, which may offer advantages over less selective SERMs like tamoxifen. However, individual response varies, and the appropriate choice depends on the specific context and goals.

Raloxifene and tamoxifen are both SERMs used for estrogen receptor modulation, but they differ in tissue selectivity. Raloxifene is described as more tissue-selective, blocking estrogen in breast tissue without blocking estrogen in the brain. Tamoxifen has more systemic estrogenic effects, which can lead to side effects that raloxifene may avoid.

Nolvadex (tamoxifen) and raloxifene are both SERMs, but raloxifene is a second-generation compound with greater tissue selectivity. Raloxifene may be preferred for gynecomastia management due to its reduced systemic estrogenic effects, while tamoxifen is more commonly used in PCT protocols.

In medical practice, 60 mg daily is the standard recommended dose for osteoporosis and breast cancer risk reduction. In non-medical bodybuilding contexts, 60 mg daily is the most commonly referenced dose for gynecomastia management. The 60 mg strength of Raloxifene 60 mg aligns with these standard reference points.

Raloxifene 60 mg is labeled at 60 mg of raloxifene hydrochloride per tablet. It is supplied in a 100-tablet package, giving 6,000 mg of total labeled raloxifene hydrochloride content.

Yes. Published laboratory reports include one dated April 18, 2025 measuring Raloxifene 60 mg at 58.23 mg/tablet (97.05% of label claim), and another dated January 4, 2024 measuring 54.15 mg/tablet (90.25% of label claim). The batch number for both reports was #HD9TX23. Complete reports can be viewed in the Lab Reports tab.

Yes. Raloxifene carries a boxed warning for increased risk of venous thromboembolism, including deep vein thrombosis and pulmonary embolism. Women with active or past history of blood clots should not take raloxifene. The risk of blood clots is increased during raloxifene therapy and may persist after discontinuation.